Article
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Blood - 11 May 2017
Barr Paul M, Brown Jennifer R, Hillmen Peter, O'Brien Susan, Barrientos Jacqueline C, Reddy Nishitha M, Coutre Steven, Mulligan Stephen P, Jaeger Ulrich, Furman Richard R, Cymbalista Florence, Montillo Marco, Dearden Claire, Robak Tadeusz, Moreno Carol, Pagel John M, Burger Jan A, Suzuki Samuel, Sukbuntherng Juthamas, Cole George, James Danelle F, Byrd John C
Abstract excerpt
Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hours. It is unknown if intermittent interruption of ibrutinib therapy contributes to altered clinical outcomes. We therefore evaluated the effect of ibrutinib dose adherence...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.